Endocrine

Hirsutism and PCOS: workup and management

Clinical Overview and When to Suspect PCOS

— Increased GnRH pulse frequency → elevated LH:FSH ratio → ovarian theca cell hyperandrogenism

— Insulin resistance (independent of BMI) amplifies ovarian androgen production and suppresses hepatic SHBG, raising free testosterone

— Anovulation produces unopposed estrogen → endometrial hyperplasia risk

— Oligo/anovulation (cycles >35 days or <8 cycles/year)

— Clinical or biochemical hyperandrogenism (hirsutism, acne, alopecia; or elevated free/total testosterone)

— Polycystic ovarian morphology on US (≥20 follicles per ovary or ovarian volume >10 mL)

— Adolescent or young adult with menstrual irregularity + acne or hirsutism

— Unexplained weight gain with acanthosis nigricans

— Subfertility after 12 months of unprotected intercourse (6 months if age ≥35)

— Incidental "polycystic ovaries" on pelvic US — imaging alone is not diagnostic

— Type 2 diabetes / prediabetes (4× risk)

— Metabolic syndrome, NAFLD, OSA

— Depression, anxiety, eating disorders

— Endometrial cancer (3× risk from chronic unopposed estrogen)

Board pearl: In adolescents, requiring all three Rotterdam criteria is recommended — irregular cycles in the first 1–2 years post-menarche are physiologic, and polycystic ovarian morphology is common and nonspecific. Diagnose adolescents only when both hyperandrogenism AND persistent oligomenorrhea are present, and defer pelvic US.

Step 3 management: A 22-year-old with 6 cycles/year and moderate facial hirsutism warrants labs to confirm hyperandrogenism and exclude mimics before labeling as PCOS — do not anchor on ultrasound findings alone.

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in reproductive-age women, prevalence 8–13%, and the leading cause of anovulatory infertility and androgen excess in this population.

Pathophysiology is a self-perpetuating loop:

Rotterdam criteria (need 2 of 3, after excluding mimics):

When to suspect in the family medicine clinic:

Associated comorbidities to screen at diagnosis:

Presentation Patterns and Key History

— Classic PCOS: obesity, oligomenorrhea, hirsutism, acne, infertility

— Lean PCOS: normal BMI but insulin resistant; often subtle hirsutism and irregular cycles — easily missed

— Ovulatory hyperandrogenic phenotype: regular cycles but androgen excess

— Age at menarche (typically normal in PCOS, ~12–13)

— Cycle length, regularity, duration since menarche — >35 day cycles or <8 menses/year = oligomenorrhea

— Primary vs secondary amenorrhea (primary suggests other etiology)

— Prior pregnancies and time-to-conception

— Hirsutism: terminal hair in male-pattern areas (upper lip, chin, chest, back, lower abdomen) — gradual onset over years favors PCOS

— Rapid-onset, severe virilization (deepening voice, clitoromegaly, male-pattern balding, muscle bulk) → suspect androgen-secreting tumor or Cushing

— Acne persisting past adolescence, treatment-resistant

— Androgenetic alopecia (crown thinning with preserved hairline)

— Weight gain pattern and central adiposity

— Acanthosis nigricans, skin tags

— Snoring, daytime somnolence (OSA screen)

— Mood symptoms, disordered eating

— Anabolic steroids, testosterone, DHEA supplements

— Valproate (associated with PCOS-like syndrome)

— Danazol, exogenous glucocorticoids

Key distinction: Gradual hirsutism since adolescence with mild lab abnormalities → PCOS. Rapid (<1 year) virilization with markedly elevated androgens → ovarian or adrenal tumor until proven otherwise — image immediately, do not delay with empiric OCP.

Board pearl: Always ask about supplement use; OTC "muscle building" or DHEA products are a frequent unrecognized cause of acquired hirsutism in young women.

Three clinical phenotypes commonly seen in ambulatory practice:

Targeted menstrual history:

Androgen excess history:

Metabolic and systems review:

Family history: PCOS, T2DM, premature CV disease, early hair loss

Medication and exposure history (critical to exclude mimics):

Physical Exam Findings

— BP (PCOS confers HTN risk independent of weight)

— BMI, waist circumference (>88 cm in women = increased metabolic risk)

— Document baseline weight for monitoring

— 9 body areas (upper lip, chin, chest, upper/lower abdomen, upper/lower back, upper arms, thighs), each scored 0–4

— Total ≥8 in most US populations = clinically significant hirsutism

— Threshold lower (≥6) in East Asian women, higher (≥9–10) in Mediterranean/South Asian populations

— Document score at baseline — needed to track response, since therapy effect takes 6+ months

— Acne distribution (face, chest, back) and severity

— Acanthosis nigricans (posterior neck, axillae, groin) — marker of insulin resistance

— Skin tags

— Androgenetic alopecia (Ludwig pattern: crown thinning, frontal hairline preserved)

— Seborrhea

— Clitoromegaly, voice deepening, temporal balding, increased muscle mass → virilization → tumor workup

— Moon facies, purple striae >1 cm, supraclavicular fat pad, proximal myopathy → Cushing

— Galactorrhea → prolactinoma

— Goiter, tremor, reflex changes → thyroid disease

— Webbed neck, short stature → Turner mosaic

— Generally normal; ovaries may be palpably enlarged but rarely needed for diagnosis

— Assess for atrophy or other structural cause of bleeding pattern

Board pearl: Hirsutism is terminal, pigmented, androgen-driven hair in male-pattern areas. Hypertrichosis is generalized fine vellus hair, often medication-induced (cyclosporine, minoxidil, phenytoin) — not androgen mediated and does not warrant hormonal workup.

Step 3 management: Always perform and document an mFG score at the initial visit; subjective "she looks hairy" is not adequate baseline for measuring later treatment response.

Vital signs and anthropometrics:

Hirsutism scoring — modified Ferriman-Gallwey (mFG):

Skin and androgen findings:

Findings that should redirect workup:

Pelvic exam:

Diagnostic Workup — Initial Labs

— Total testosterone (best initial androgen test); mild elevation (<150 ng/dL) typical in PCOS

— Free testosterone or calculated free T (SHBG often low in PCOS → free T disproportionately elevated)

— DHEA-S (adrenal androgen) — mild elevation possible in PCOS; markedly elevated (>700 µg/dL) suggests adrenal tumor

— 17-hydroxyprogesterone (morning, follicular phase) to screen non-classic CAH; >200 ng/dL warrants ACTH stimulation test

— TSH (hypothyroidism causes oligomenorrhea)

— Prolactin (modest elevation possible in PCOS; >100 ng/mL suggests prolactinoma)

— β-hCG if any amenorrhea — always exclude pregnancy first

— 24-hour urinary free cortisol, late-night salivary cortisol, or 1-mg overnight dexamethasone suppression

— 2-hour 75-g OGTT preferred (HbA1c and fasting glucose miss ~30% of dysglycemia in PCOS)

— Fasting lipid panel

— LFTs (NAFLD screen)

— BP at every visit

Board pearl: Testosterone >150–200 ng/dL or DHEA-S >700 µg/dL, or rapid virilization, mandates imaging (transvaginal US for ovarian tumor, adrenal CT for adrenal tumor) — do not attribute to PCOS.

Step 3 management: OGTT, not HbA1c alone, is the preferred dysglycemia screen at PCOS diagnosis and every 1–3 years thereafter per Endocrine Society and international PCOS guidelines.

PCOS is a diagnosis of exclusion — initial labs both support PCOS and rule out mimics. Order on cycle day 2–5 if menstruating; any day if amenorrheic.

Core hormonal panel:

If clinical features of Cushing (striae, easy bruising, central obesity with thin extremities, hypertension):

LH and FSH: not required for diagnosis; LH:FSH >2 supports but is neither sensitive nor specific

AMH: elevated in PCOS but not part of formal criteria; do not order routinely

Metabolic screening at diagnosis (all patients):

Diagnostic Workup — Advanced and Confirmatory Studies

— Indicated when needed to fulfill Rotterdam criteria (i.e., only one of the other two features present in an adult)

— Polycystic ovarian morphology = ≥20 follicles (2–9 mm) per ovary or ovarian volume >10 mL (using modern high-frequency transducers)

— Defer in adolescents within 8 years of menarche (high false-positive rate)

— Also evaluates endometrial thickness; endometrial stripe >7 mm in anovulatory patient warrants biopsy

— Indicated if baseline 17-OHP >200 ng/dL

— 17-OHP >1000 ng/dL at 60 minutes after 250 µg cosyntropin = non-classic 21-hydroxylase deficiency CAH

— Higher prevalence in Ashkenazi Jewish, Hispanic, Mediterranean populations

— TVUS or pelvic MRI for ovarian source

— Adrenal CT with contrast for adrenal source

— Selective venous sampling rarely needed

— Prolonged amenorrhea (>1 year) with no progestin protection

— Abnormal uterine bleeding

— Endometrial stripe >7 mm in chronic anovulation

— Age ≥45 with abnormal bleeding, or younger with persistent risk factors (obesity, Lynch)

Key distinction: Polycystic ovarian morphology on US is found in ~20% of normal reproductive-age women — imaging alone never establishes PCOS. Always pair with clinical/biochemical criteria.

Board pearl: Any PCOS patient with >3 months of amenorrhea needs progestin withdrawal or cyclic protection to prevent endometrial hyperplasia — and biopsy if bleeding becomes abnormal.

Transvaginal ultrasound (TVUS):

ACTH stimulation test:

Tumor workup if androgens markedly elevated or rapid virilization:

Cushing confirmation: if initial screen positive, repeat with a second modality, then ACTH and pituitary/adrenal imaging

Endometrial biopsy indications:

OSA evaluation: STOP-BANG or Epworth; refer for polysomnography if positive — OSA prevalence in PCOS approaches 30–50%

NAFLD: if elevated transaminases or metabolic syndrome, RUQ US ± FIB-4

Risk Stratification and Management Logic

— A. Menstrual regulation / endometrial protection

— B. Hyperandrogenism (hirsutism, acne, alopecia)

— C. Fertility (currently desiring pregnancy?)

— D. Metabolic risk reduction (weight, dysglycemia, lipids, BP)

— E. Mental health

— Not pursuing pregnancy + hyperandrogenism + irregular menses → combined OCP is the single best first-line agent (addresses A and B simultaneously)

— Pursuing pregnancy → OCPs contraindicated; use letrozole for ovulation induction

— Predominant metabolic concern → lifestyle ± metformin

— Persistent hirsutism despite OCP at 6 months → add spironolactone

— 5–10% weight loss restores ovulation in many overweight/obese patients

— Mediterranean or DASH-style diet, ≥150 min/week moderate aerobic activity plus 2 days resistance training

— Sleep hygiene; treat OSA

— OGTT every 1–3 years (annually if prediabetes, GDM history, or marked obesity)

— Lipid panel every 2 years (annually if dyslipidemic)

— BP every visit

— Depression/anxiety screen annually (PHQ-9, GAD-7)

— Endometrial assessment if abnormal bleeding or prolonged amenorrhea

Step 3 management: The single most high-yield ambulatory question is "Is pregnancy desired now?" — the answer flips first-line therapy from combined OCP to letrozole. Ask it at every visit.

Board pearl: Even normal-BMI ("lean") PCOS patients carry elevated dysglycemia risk and require the full metabolic screen — do not skip OGTT based on weight.

Management is goal-directed, not one-size-fits-all. Establish each visit's priority:

Decision branches:

Lifestyle is foundational for all patients:

Screening cadence after diagnosis:

Cardiovascular risk: PCOS is a risk-enhancing factor in the ACC/AHA ASCVD framework — factor into statin decision-making in borderline-risk women

Pharmacotherapy — First-Line Regimens

— Mechanism: suppress LH → ↓ ovarian androgen production; estrogen ↑ SHBG → ↓ free T; progestin opposes endometrial proliferation

— Prefer formulations with low-androgenic progestins (norgestimate, desogestrel, drospirenone)

— Start any low-dose 20–35 µg ethinyl estradiol pill; specific brand matters less than adherence

— Contraindications: migraine with aura, smoker ≥35, uncontrolled HTN, VTE history, breast cancer, active liver disease, <6 weeks postpartum

— Hirsutism response requires 6 months — counsel on timeline

— Dose 50–200 mg/day (often 100 mg)

— Monitor potassium at baseline and 4 weeks (esp. with ACEi/ARB, renal impairment)

— Teratogenic (feminization of male fetus) — must pair with reliable contraception

— Also helps androgenetic alopecia and acne

— Start 500 mg with dinner, titrate to 1500–2000 mg/day

— Modest benefit on menstrual regularity and weight; minimal effect on hirsutism

— Hold for contrast studies if eGFR <30; avoid eGFR <30

— Eflornithine 13.9% cream twice daily for facial hirsutism (slows hair growth; works synergistically with laser/electrolysis)

— Topical retinoids and benzoyl peroxide for acne

Board pearl: Spironolactone monotherapy without contraception in a sexually active patient is a board trap — always co-prescribe a COC or document a non-hormonal method.

Step 3 management: Set the 6-month expectation up front; premature switching of COC because "hair didn't go away in 2 months" is a common pitfall.

Combined oral contraceptives (COCs) — first-line for menstrual regulation, hirsutism, acne when pregnancy not desired:

Spironolactone — antiandrogen, added when hirsutism inadequately controlled on COC or as alternative if COC contraindicated:

Metformin — primary indication is dysglycemia (prediabetes/T2DM) or BMI ≥25 with metabolic syndrome features:

Topical therapy:

Mechanical hair reduction: laser (best for dark hair, light skin) and electrolysis are highly effective and often necessary alongside hormonal therapy

Expanded Pharmacology — Fertility and Second-Line Agents

— Letrozole = first-line (aromatase inhibitor): 2.5 mg days 3–7 of cycle; higher live birth rate than clomiphene in PCOS (PPCOS II trial)

— Clomiphene citrate = alternative SERM: 50 mg days 5–9; risk of multiple gestation ~7%, antiestrogenic endometrial effect

— Metformin adjunct: improves ovulation rates, may reduce miscarriage and OHSS risk; especially useful with BMI >30

— If unsuccessful after 3–6 cycles → refer to reproductive endocrinology for gonadotropins, laparoscopic ovarian drilling, or IVF

— Optimize weight, glycemic control (target HbA1c <6.5% if diabetic), BP, folic acid 400–800 µg/day (1 mg if T2DM)

— Screen and treat OSA

— Discontinue teratogens (spironolactone, statins, ACEi/ARB, finasteride)

— Counsel on increased risk of GDM, preeclampsia, preterm birth, miscarriage

— Finasteride 2.5–5 mg daily (5α-reductase inhibitor) — useful for alopecia

— Flutamide — hepatotoxicity limits use

— Cyproterone acetate — not available in US

— Increasingly used for obesity in PCOS; improve weight, insulin sensitivity, menstrual regularity

— Not first-line; discontinue ≥2 months before attempting conception (animal teratogenicity signal)

Key distinction: Letrozole > clomiphene for ovulation induction in PCOS — higher live birth rate, lower multiple gestation risk. This reversed prior teaching and is a frequently tested update.

Board pearl: A PCOS patient on metformin who becomes pregnant can typically continue it through pregnancy if needed for glycemic control, but it is not used solely to prevent miscarriage in routine PCOS.

Ovulation induction (pregnancy desired):

Pre-conception counseling:

Second-line antiandrogens (used off-label, all teratogenic — require contraception):

GLP-1 receptor agonists (semaglutide, liraglutide):

Inositol (myo-inositol 2 g BID): modest evidence for ovulation and metabolic parameters; reasonable adjunct

Special Populations — Renal, Hepatic, and Older Patients

— Spironolactone: avoid if eGFR <30; use cautiously eGFR 30–60 with potassium monitoring every 4 weeks initially; avoid with concurrent ACEi/ARB + NSAIDs (triple whammy)

— Metformin: dose-reduce eGFR 30–45 (max 1000 mg/day); discontinue eGFR <30; hold 48 h before/after IV contrast if eGFR <60

— COCs: generally safe in CKD without proteinuria; avoid in nephrotic syndrome (VTE risk)

— Avoid COCs in active liver disease, decompensated cirrhosis, or history of estrogen-induced cholestasis

— Avoid flutamide; caution with statins and metformin (avoid in acute hepatitis or decompensated disease)

— Letrozole metabolized hepatically; reduce dose in severe impairment

— Androgen levels and ovarian volume decline with age; some PCOS features attenuate

— However, metabolic risk persists and accelerates — continue annual dysglycemia, lipid, and BP screening

— Endometrial cancer risk remains elevated; investigate any postmenopausal bleeding promptly

— Hirsutism in postmenopausal women: new-onset = workup for tumor (ovarian hyperthecosis, androgen-secreting tumor) — do not assume PCOS

— Stop estrogen-containing COCs 4 weeks before major surgery (VTE risk), restart 2 weeks after mobilization

— GLP-1 agonists: hold per anesthesia protocol (typically 1 week before for weekly agents) due to aspiration risk from delayed gastric emptying

— Continue metformin until day of surgery; resume when eating

Step 3 management: A 58-year-old with new facial hair growth over 6 months and testosterone 180 ng/dL — this is not late PCOS; image the ovaries and adrenals.

Board pearl: The "triple whammy" of spironolactone + ACEi/ARB + NSAID precipitates AKI and hyperkalemia — a frequent ambulatory safety pearl.

Renal impairment:

Hepatic impairment:

Perimenopause and beyond:

Perioperative considerations:

Special Populations — Adolescents and Pregnancy

— Require both hyperandrogenism (clinical or biochemical) AND persistent oligo/amenorrhea

— Do not use pelvic US for diagnosis

— Many will have "at-risk" features without meeting criteria — re-evaluate periodically rather than label prematurely

— First-line treatment mirrors adults: lifestyle + COC for menstrual/androgenic concerns; metformin if dysglycemia or BMI ≥25 with metabolic features

— Address body image, mental health, and contraception counseling proactively

— Miscarriage (especially first trimester)

— Gestational diabetes — screen with early OGTT at first prenatal visit, repeat 24–28 weeks if initial normal

— Hypertensive disorders of pregnancy (preeclampsia ~3× risk)

— Preterm birth, LGA infants, NICU admission

— Increased C-section rate

— Aspirin 81 mg daily from 12 weeks if additional preeclampsia risk factors (most PCOS patients qualify when combined with obesity or chronic HTN)

— Glycemic control: lifestyle, metformin or insulin as needed

— Continue prenatal vitamins with folate; vitamin D repletion if deficient

— Stop before/during pregnancy: spironolactone, finasteride, flutamide, statins, ACEi/ARB, GLP-1 agonists

— Acceptable if needed: metformin (continued use generally safe), insulin, labetalol/nifedipine for HTN

— Repeat OGTT at 6–12 weeks postpartum if GDM

— Lifetime annual diabetes screening after GDM

— Lactation: progestin-only contraception preferred in first 6 weeks; COC after if not contraindicated

Key distinction: GDM history + PCOS confers very high lifetime T2DM risk — counsel on aggressive lifestyle and consider metformin for prediabetes prevention.

Board pearl: Order early pregnancy OGTT at the first prenatal visit in any PCOS patient — do not wait until 24–28 weeks.

Adolescents (within 8 years of menarche):

Pregnancy in PCOS — heightened risks:

Antepartum management:

Medications in pregnancy:

Postpartum:

Complications and Adverse Outcomes

— Infertility / subfertility (anovulation)

— Pregnancy complications (above)

— Endometrial hyperplasia and adenocarcinoma — 3-fold increased risk from chronic unopposed estrogen

— Possibly increased ovarian cancer risk (data mixed); breast cancer risk not consistently elevated

— Type 2 diabetes — onset 10–20 years earlier than general population

— Prediabetes prevalence ~30–40%

— Metabolic syndrome in 30–50%

— NAFLD/NASH — leading cause of elevated transaminases in PCOS

— Dyslipidemia: ↑ triglycerides, ↑ LDL, ↓ HDL

— Hypertension

— Subclinical atherosclerosis markers elevated

— Listed as CV risk-enhancing factor in ACC/AHA guidelines; consider statin in borderline-risk women

— OSA independent of BMI — screen routinely

— Depression (~3× risk), anxiety, eating disorders (binge eating, bulimia), poor body image, reduced quality of life

— Increased suicidality — screen with PHQ-9/GAD-7 annually

— COC: VTE, BP elevation, mood changes, breakthrough bleeding

— Spironolactone: hyperkalemia, hypotension, menstrual irregularity, breast tenderness

— Metformin: GI upset, B12 deficiency (check level after 4–5 years), rare lactic acidosis

— Letrozole/clomiphene: hot flashes, multiple gestation, OHSS

Step 3 management: Annual depression screening with PHQ-9 is a guideline-level recommendation in PCOS — frequently tested and easily forgotten alongside the metabolic emphasis.

Board pearl: Check vitamin B12 in long-term metformin users; deficiency presents as macrocytic anemia, neuropathy, or both.

Reproductive:

Metabolic:

Cardiovascular:

Sleep/respiratory:

Psychiatric:

Dermatologic and cosmetic: persistent hirsutism, acne scarring, alopecia — significant psychosocial morbidity

Pharmacologic adverse effects:

When to Escalate Care — Consults and Referrals

— Diagnostic uncertainty (atypical features, markedly elevated androgens)

— Suspected non-classic CAH or Cushing

— Refractory hyperandrogenism despite COC + spironolactone

— Difficult-to-control diabetes attributable to severe insulin resistance

— Failure to conceive after 3–6 cycles of letrozole

— Need for gonadotropins, IUI, IVF

— Recurrent pregnancy loss

— Tubal or male factor coexisting

— Abnormal uterine bleeding requiring biopsy or hysteroscopy

— Endometrial stripe >7 mm in anovulatory patient

— Need for IUD placement (levonorgestrel IUD is excellent for endometrial protection in patients who can't tolerate COC)

— Confirmed endometrial hyperplasia with atypia or endometrial carcinoma

— Suspected ovarian androgen-secreting tumor

— Rapid virilization → urgent imaging within days

— Heavy abnormal uterine bleeding with hemodynamic compromise → ED

— DKA or HHS in undiagnosed diabetes → ED

Step 3 management: Most PCOS care lives in the primary care home — escalate when diagnostic features are atypical, treatment fails at 6 months, or fertility services are needed. Routine, stable PCOS does not require ongoing endocrinology follow-up.

Board pearl: A levonorgestrel IUD provides excellent endometrial protection and is the preferred option when COCs are contraindicated (smoker ≥35, migraine with aura, VTE history).

Endocrinology referral:

Reproductive endocrinology/infertility (REI):

Gynecology:

Gynecologic oncology:

Dermatology: severe acne, scarring, refractory alopecia, laser hair removal coordination

Sleep medicine: positive OSA screen

Hepatology: persistently elevated transaminases, suspected NASH with fibrosis (FIB-4 >1.3)

Behavioral health/psychiatry: moderate-severe depression, suicidal ideation, eating disorder

Nutrition/dietitian: structured weight management, prediabetes/T2DM, bariatric evaluation candidacy (BMI ≥35 with comorbidity)

Urgent/emergent escalation:

Key Differentials — Other Endocrine Causes of Hirsutism/Oligomenorrhea

— 21-hydroxylase deficiency, autosomal recessive

— Indistinguishable clinically from PCOS — hirsutism, acne, irregular menses, infertility

— Screen: morning follicular-phase 17-OHP >200 ng/dL → confirm with ACTH stim (60-min 17-OHP >1000)

— Treatment: low-dose glucocorticoid (prednisone 2.5–5 mg or hydrocortisone) if symptomatic or infertile; otherwise often treated like PCOS

— Central obesity, moon facies, supraclavicular fat, wide purple striae, proximal myopathy, easy bruising, hypertension, hyperglycemia

— Screen: 24-h urinary free cortisol, late-night salivary cortisol, 1-mg dexamethasone suppression

— Ovarian (Sertoli-Leydig, hilus cell) — testosterone often >150–200 ng/dL

— Adrenal (adenoma or carcinoma) — DHEA-S often >700 µg/dL

— Rapid virilization (<1 year), high androgens → image

— Galactorrhea, oligomenorrhea, headache, visual changes

— Prolactin >100 ng/mL strongly suggests adenoma → pituitary MRI

— Hypothyroidism → oligomenorrhea, menorrhagia, weight gain

— Hyperthyroidism → oligomenorrhea, weight loss

— Postmenopausal hirsutism/virilization with elevated testosterone but normal imaging

— Often confused with tumor; managed with GnRH agonists or oophorectomy

— Amenorrhea + elevated FSH + low estradiol — opposite hormonal pattern from PCOS

Key distinction: PCOS = androgens mildly elevated, FSH normal/low, gradual onset. POI = androgens normal, FSH high, often hot flashes. Tumor = androgens markedly elevated, rapid virilization.

Board pearl: Always screen 17-OHP at diagnosis — NCCAH is the single most common PCOS mimic and is often missed.

Non-classic congenital adrenal hyperplasia (NCCAH):

Cushing syndrome:

Androgen-secreting tumors:

Hyperprolactinemia/prolactinoma:

Thyroid disorders:

Acromegaly: rare, but causes insulin resistance, irregular menses, coarse features — IGF-1 screen

Ovarian hyperthecosis:

Premature ovarian insufficiency:

Key Differentials — Non-Endocrine and Drug-Induced Causes

— Hirsutism with regular ovulatory cycles and normal androgens

— Increased peripheral 5α-reductase activity in hair follicles

— Treat with spironolactone, eflornithine, mechanical removal; COC also effective

— Hirsutism + elevated androgens, but regular cycles and normal ovaries — variant on PCOS spectrum

— Generalized vellus hair, not androgen-mediated, not male-pattern

— Causes: medications (minoxidil, cyclosporine, phenytoin, diazoxide), porphyria, anorexia (lanugo), paraneoplastic

— No hormonal workup required if classic medication-related pattern

— Anabolic steroids, exogenous testosterone (including OTC creams and gels)

— DHEA supplements

— Danazol (endometriosis)

— Valproate (PCOS-like syndrome, especially in epilepsy patients)

— Always take a detailed supplement and partner medication history (transfer from topical testosterone gels in a partner is a recognized exposure)

— Low BMI, eating disorder, athlete, stress

— Low LH and FSH, low estradiol, no hyperandrogenism

— Opposite metabolic profile from PCOS; treat with restoration of energy availability

— Asherman syndrome (intrauterine adhesions post-D&C), cervical stenosis

— No androgen excess; diagnose with imaging or hysteroscopy

Key distinction: Hypothalamic amenorrhea (low LH/FSH, low estrogen, often underweight) and PCOS (normal/high LH, normal estrogen, often overweight) sit at opposite ends of the menstrual irregularity spectrum — distinguishing them prevents harmful misdiagnosis.

Board pearl: Always re-examine the medication list and OTC supplement use in a hirsute patient — drug-induced androgen excess is reversible and underrecognized.

Idiopathic hirsutism:

Idiopathic hyperandrogenism:

Hypertrichosis (distinguish from hirsutism):

Drug-induced androgen excess:

Hypothalamic amenorrhea:

Structural causes of amenorrhea:

Pregnancy: always rule out first in any patient with new amenorrhea

Long-Term Plan and Preventive Strategy

— PCOS is a lifelong metabolic and reproductive condition — frame discussions around decades of management, not single-visit fixes

— Reassess goals at every visit (contraception, fertility, weight, mood)

— Combined OCP for cycle regulation/androgen control (continue indefinitely if tolerated and pregnancy not desired; reassess CV risk at 35 and again at 40)

— Spironolactone for hirsutism (long-term safe with periodic K+ monitoring)

— Metformin for dysglycemia or insulin resistance

— Statin if ASCVD risk warrants (factor PCOS as risk-enhancer in borderline categories)

— Antihypertensives as needed; ACEi/ARB preferred in dysglycemic patients

— Cervical cancer screening per age guidelines

— Breast cancer screening per age guidelines

— Depression and anxiety screening annually

— Tobacco cessation (especially before age 35 if on COC)

— Vaccinations: HPV (through age 26, shared decision 27–45), influenza annually, COVID-19 per current recs, Tdap

— Pre-conception counseling reviewed yearly in reproductive-age patients

— Annual weight, waist, BP, BMI documentation

— Refer to structured programs; consider GLP-1 agonist or bariatric surgery (BMI ≥35 with comorbidity, or ≥40) when appropriate

— COC, levonorgestrel IUD, cyclic progestin (e.g., medroxyprogesterone 10 mg × 10–14 days every 1–3 months), or restoration of ovulatory cycles

Step 3 management: Every PCOS chart should have a documented endometrial protection strategy — anovulatory patients with no progestin coverage for >3 months are at active hyperplasia risk and require an action.

Board pearl: PCOS qualifies as an ASCVD risk-enhancing factor — use it to nudge borderline-risk women (5–7.5% 10-year risk) toward statin therapy.

Anchoring the chronic care plan:

Ongoing medications (typical maintenance regimen):

Preventive care (USPSTF and PCOS-specific):

Weight management as ongoing intervention:

Endometrial protection plan documented in chart:

Follow-Up, Monitoring, and Counseling

— Newly diagnosed: follow-up at 3 months to assess medication tolerance, side effects, BP, weight

— Stable on therapy: every 6–12 months

— Adjusting fertility therapy or active weight management: more frequent (monthly during letrozole cycles)

— COC: BP at 3 months, then annually; review VTE risk factors yearly; screen for smoking

— Spironolactone: baseline K+ and Cr, repeat at 4 weeks after initiation or dose change; annually thereafter if stable

— Metformin: renal function annually; B12 every 1–2 years after 4+ years of use

— Letrozole/clomiphene: mid-luteal progesterone (>3 ng/mL = ovulation), early pregnancy assessment

— Acne: improvement 2–3 months

— Menstrual regularity: 1–3 cycles

— Hirsutism: 6 months minimum before judging response; maximal effect 12 months

— Weight loss: 5–10% over 6 months is realistic and clinically meaningful

— Hirsutism is best managed with hormonal + mechanical (laser/electrolysis) in combination — set this expectation

— Eflornithine slows facial hair growth; doesn't remove it

— COC does not cause infertility — a common patient concern; clarify clearly

— Discuss long-term diabetes and CV risk without inducing anxiety; frame as actionable

— Address mental health proactively; normalize referral

— Menstrual diary

— mFG score (every 6 months)

— BP, weight, waist

— Mood screen

— Pregnancy intention

Step 3 management: A patient returning at 3 months saying "the pill isn't working — I'm still hairy" needs reassurance and continued therapy, not a regimen change — hirsutism takes 6 months to respond.

Board pearl: Document a baseline mFG score; without it, you cannot measure response objectively and risk premature regimen changes.

Visit cadence:

Monitoring parameters by therapy:

Treatment response expectations — counsel up front:

Counseling pearls:

Documentation each visit:

Ethical, Legal, and Patient Safety Considerations

— Most US states permit minors to consent to contraceptive services without parental notification

— Discuss confidentiality limits at the start of the visit; offer time with the patient alone

— Document shared decision-making for COC initiation in minors

— Spironolactone, finasteride, flutamide, statins, ACEi/ARB, GLP-1 agonists all require effective contraception

— Document contraceptive method in chart at every prescription

— A documented pregnancy plan or reliable contraception is a patient-safety requirement, not optional

— Letrozole for ovulation induction is off-label but guideline-recommended — discuss and document

— Spironolactone for hirsutism is also off-label; obtain verbal informed consent

— High suicide risk in PCOS — annual screening with PHQ-9; create a safety plan if positive ideation; same-day behavioral health connection when feasible

— Eating disorder screening (SCOFF) particularly with weight-focused counseling — avoid harmful weight stigma

— Hirsutism therapies (laser, electrolysis, eflornithine) are often not insurance-covered — discuss costs and prioritize hormonal therapy

— Bariatric surgery and GLP-1 agonist access varies — advocate when appropriate

— Adolescent-to-adult care transition: ensure transfer summary includes diagnostic criteria met, endometrial protection plan, metabolic screening status, and contraceptive plan

— Pre-conception transition: confirm teratogenic medications discontinued before stopping contraception

— Premature labeling of adolescents as "PCOS" carries lifelong insurance, psychological, and treatment implications — adhere to stricter adolescent criteria

Step 3 management: A 19-year-old on spironolactone for acne who reports becoming sexually active without contraception requires same-visit contraception initiation and counseling on teratogenic risk — do not let this slide to next visit.

Board pearl: Documented contraception is a board-tested safety requirement whenever antiandrogens are prescribed in reproductive-age women.

Adolescent confidentiality:

Teratogenicity counseling — critical safety issue:

Informed consent for off-label use:

Mental health safety net:

Health equity and access:

Transition-of-care safety:

Avoiding diagnostic harm:

High-Yield Associations and Rapid-Fire Facts

Board pearl: When the stem says "regular cycles, normal androgens, but cosmetically distressing hair" — that's idiopathic hirsutism, not PCOS. Treat with spironolactone + COC + mechanical removal anyway.

Key distinction: PCOS is fundamentally a diagnosis of exclusion with mild lab abnormalities and gradual onset — anything rapid or dramatic should redirect your workup.

Rotterdam = 2 of 3: oligo/anovulation, hyperandrogenism, polycystic ovaries (after exclusion)

Adolescents: require both hyperandrogenism AND oligomenorrhea; no US

Letrozole > clomiphene for ovulation induction in PCOS (live birth rate)

Hirsutism response to COC: 6 months — counsel up front

Testosterone >150–200 or DHEA-S >700, or rapid virilization → image for tumor

17-OHP >200 ng/dL → ACTH stim for non-classic CAH

OGTT preferred over A1c for dysglycemia screening in PCOS; repeat every 1–3 years

Endometrial protection required if amenorrhea >3 months: COC, LNG-IUD, or cyclic progestin

Endometrial stripe >7 mm in anovulatory patient with bleeding → biopsy

Spironolactone is teratogenic — always pair with contraception

PCOS = CV risk-enhancing factor in ACC/AHA guidelines

GDM screening at first prenatal visit in PCOS, repeat 24–28 weeks

OSA prevalence 30–50% in PCOS — screen with STOP-BANG/Epworth

NAFLD common — RUQ US if transaminases elevated

Metformin + long-term use → check B12

Lean PCOS exists — still screen metabolic risks

Hypothalamic amenorrhea = low LH/FSH, low estrogen, low BMI — opposite of PCOS

Hypertrichosis ≠ hirsutism; vellus hair, often drug-induced

Postmenopausal new hirsutism → tumor or hyperthecosis, not PCOS

Drospirenone-containing COCs have mild antiandrogenic activity — useful for acne/hirsutism but higher VTE signal than levonorgestrel

Valproate can cause PCOS-like syndrome — consider alternative in young women with epilepsy

GLP-1 agonists improve weight/insulin sensitivity but stop ≥2 months before conception

Levonorgestrel IUD is excellent endometrial protection when COC contraindicated

Annual depression screening is guideline-recommended in PCOS

Pre-conception check: stop teratogens, optimize weight/glucose/BP, folic acid, aspirin if preeclampsia risk

Board Question Stem Patterns

Step 3 management: Always read for the goal (pregnancy now? cosmetic? metabolic?) and the red flag (rapid virilization, extreme labs, postmenopausal onset). Both determine the right answer.

Classic Rotterdam stem: 24-year-old with 6 menses/year, acne, mFG 12, BMI 31, total T 75 ng/dL, normal 17-OHP, TSH, prolactin, β-hCG. Best next step? → Lifestyle + combined OCP (not pregnancy-seeking)

Pregnancy-desiring PCOS: Same patient now wants pregnancy. Best next step? → Letrozole ovulation induction (not clomiphene, not OCP)

Tumor red flag: 28-year-old with 6-month rapid virilization, voice deepening, clitoromegaly, T 320 ng/dL. Best next step? → Transvaginal US ± adrenal CT, not COC

NCCAH disguised as PCOS: Hispanic 22-year-old with classic features but 17-OHP 350 ng/dL. Best next step? → ACTH stimulation test

Adolescent overdiagnosis trap: 15-year-old, menarche at 13, irregular cycles, US shows polycystic ovaries, no hirsutism, normal labs. Diagnosis? → Not PCOS — physiologic, observe

Endometrial protection: PCOS patient with no menses in 8 months, on no medication, light bleeding × 2 weeks. Best next step? → Endometrial biopsy (or stripe assessment first if young/no risk factors)

Metabolic screening: Newly diagnosed PCOS, BMI 24. Best initial dysglycemia test? → 75-g 2-hour OGTT

Drug safety trap: 26-year-old started on spironolactone 100 mg for hirsutism, sexually active, no contraception. Most important counseling? → Initiate contraception (teratogenicity)

Hypothalamic amenorrhea distractor: Thin 19-year-old runner with amenorrhea, no hirsutism, low LH/FSH, low estradiol. Diagnosis? → Functional hypothalamic amenorrhea, not PCOS

Pregnant PCOS: Newly pregnant PCOS patient at first prenatal visit. Best initial test? → Early OGTT

CV risk: 42-year-old with PCOS, LDL 145, 10-year ASCVD risk 6.8%. Best next step? → Initiate moderate-intensity statin (PCOS = risk enhancer)

Postmenopausal hirsutism: 60-year-old with new chin hair × 8 months, T 165 ng/dL. Best next step? → Pelvic and adrenal imaging

Hirsutism response: Patient on COC × 8 weeks, frustrated no change in hair. Best next step? → Reassure and continue — 6-month timeline

B12 deficiency: Long-term metformin user with neuropathy and macrocytic anemia. Best test? → Serum B12

One-Line Recap

PCOS is a clinical diagnosis of exclusion defined by the Rotterdam criteria, managed in primary care by addressing four parallel goals — menstrual/endometrial protection, hyperandrogenism, fertility, and lifelong metabolic-cardiovascular risk — with combined OCPs (or letrozole when pregnancy is desired), spironolactone, metformin, and aggressive lifestyle intervention.

Board pearl: The single most consequential question at every PCOS visit is "Do you want to become pregnant now?" — that answer flips the entire treatment algorithm from COC-based suppression to letrozole-based induction, and reframes safety priorities around teratogenic medications, glycemic control, and pre-conception folate.

Step 3 management: Build the longitudinal chart around four documented elements at every visit — endometrial protection plan, contraception/pregnancy intention, metabolic screening date, and mental health screen — and PCOS care becomes both exam-correct and patient-centered.

Diagnose with 2 of 3 Rotterdam criteria after excluding pregnancy, thyroid disease, hyperprolactinemia, NCCAH (17-OHP), Cushing, and androgen-secreting tumors; in adolescents require both hyperandrogenism and oligomenorrhea and skip ultrasound.

Treat by goal: combined OCP first-line for non-pregnancy-seeking patients with menstrual and androgen concerns; add spironolactone at 6 months if hirsutism persists; letrozole first-line for ovulation induction; metformin for dysglycemia and BMI ≥25 with metabolic features; lifestyle for all.

Screen and protect lifelong: OGTT every 1–3 years, lipids every 2 years, BP and depression annually, endometrial protection if amenorrhea >3 months, OSA and NAFLD screening, pre-conception optimization with discontinuation of teratogens.

Watch for red flags that aren't PCOS: rapid virilization, testosterone >150–200, DHEA-S >700, new postmenopausal hirsutism, low LH/FSH with low estradiol (hypothalamic amenorrhea), or hypertrichosis from medications — each demands a different workup.